

# Elevated Serum Interleukin 33 Is Associated with Autoantibody Production in Patients with Rheumatoid Arthritis

RONG MU, HE-QING HUANG, YU-HUI LI, CHUN LI, HUA YE, and ZHAN-GUO LI

**ABSTRACT. Objective.** Interleukin 33 (IL-33) is a novel cytokine involved in joint inflammation in animal models. We analyzed the expression of IL-33 in the serum and synovial fluid of patients with rheumatoid arthritis (RA) and investigated its possible pathophysiological importance.

**Methods.** The concentration of IL-33 was measured by ELISA in the serum of 223 patients with RA and 159 controls. Anticyclic citrullinated peptide, rheumatoid factor (RF)-IgA, and RF-IgG were tested by ELISA. Antikeratin antibody and antiperinuclear factor were tested by indirect immunofluorescence assay. Erythrocyte sedimentation rate, C-reactive protein, and immunoglobulins were measured by standard laboratory techniques. The association of IL-33 level with clinical and serologic features of RA was analyzed. We tested the change of IL-33 level following tumor necrosis factor (TNF- $\alpha$ ) blockade therapy in 40 patients with RA.

**Results.** In contrast to almost no detectable IL-33 in osteoarthritis and healthy serum, IL-33 could be detected in 94 out of the 223 RA cases (42.2%). Serum IL-33 concentration was significantly higher in patients with RA than in control groups. The level of serum IL-33 decreased after anti-TNF treatment. The level of serum IL-33 was correlated with the production of IgM and RA-related autoantibodies including RF and anticitrullinated protein antibodies. However, no correlation was found between IL-33 concentration and acute-phase inflammation reactant or the score of the Disease Activity Index, suggesting a complex or indirect character of the link between IL-33 and the inflammation in RA.

**Conclusion.** The level of IL-33 is abnormally elevated in RA serum. The elevation of serum IL-33 was at least partly attributed to excessive TNF- $\alpha$  in RA. IL-33 might be involved in the regulation of autoantibody production in RA. (J Rheumatol First Release August 1 2010; doi:10.3899/jrheum.100184)

*Key Indexing Terms:*

SERUM INTERLEUKIN 33

RHEUMATOID ARTHRITIS

AUTOANTIBODIES

Rheumatoid arthritis (RA) is a common autoimmune disease that frequently leads to severe joint damage, early disability, and premature death. Although the precise etiology is unknown, cytokines appear to play an important role in the development and course of the disease<sup>1,2,3,4</sup>. RA is characterized by impaired function of T and B cells<sup>5,6,7,8</sup> and abnormal production of cytokines and autoantibodies<sup>9,10</sup>. Cytokines could have various important activities in the

context of the pathogenesis of RA, for example, inducing antibody production by B cells<sup>11,12</sup>. Biological agents directed to cytokines such as tumor necrosis factor (TNF- $\alpha$ ) and interleukin 6 (IL-6) have demonstrated dramatic efficacy in the treatment of RA<sup>4,13,14</sup>.

IL-33 is a newly described cytokine of the IL-1 family, which also includes IL-1 $\alpha$ , IL-1 $\beta$ , and IL-18<sup>15</sup>. It was identified as a ligand for the orphan receptor ST2<sup>15,16</sup>. IL-33 locates mainly in the nucleus and may regulate the expression of some genes, but its biological function and mechanism are elusive<sup>17</sup>. Most members of the IL-1 family are proinflammatory cytokines in RA. A previous study demonstrated that IL-33 could exacerbate collagen-induced arthritis (CIA) and elevate production of proinflammatory cytokines and anticollagen antibodies<sup>18</sup>. In addition, an ST2 antibody that blocks IL-33 signaling could attenuate the severity of CIA<sup>19</sup>. These studies suggest that IL-33 contributes to the pathogenesis of joint inflammation and destruction.

We speculate that IL-33 is associated with disease profiles and that serum IL-33 could be used as a marker of inflammation in RA. However, whether IL-33 is released

---

*From the Department of Rheumatology and Immunology, People's Hospital, Peking University Medical School, Beijing; and the Department of Rheumatology and Endocrinology, Fujian Medical University, Fuzhou, China.*

*Supported by the National Basic Research Program of China (973 program, 2010CB529100), and Research and Development Funding of People's Hospital, Peking University (RDB 2008-23).*

*R. Mu, MD; Y-H. Li, MD; C. Li, MD; H. Ye, MD; Z-G. Li, MD, PhD, Department of Rheumatology and Immunology, People's Hospital, Peking University Medical School; H-Q. Huang, Department of Rheumatology and Endocrinology, Fujian Medical University.*

*Address correspondence to Dr. Z-G. Li, Department of Rheumatology and Immunology, People's Hospital, Peking University, Beijing 100044, China. E-mail: zgli98@yahoo.com*

*Accepted for publication May 26, 2010.*

---

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2010. All rights reserved.

into circulation in RA remains to be determined. Studies are needed on the relationship between serum IL-33 and the clinical profiles of RA. In our study, we compared the level of IL-33 in sera obtained from patients with RA to sera in patients with primary Sjögren's syndrome (pSS), patients with osteoarthritis (OA), and healthy controls, and analyzed the association of the concentration with disease activity and serologic features in patients with RA.

## MATERIALS AND METHODS

**Patients and controls.** Serum samples were obtained from 223 consecutive patients with RA (161 women, 62 men) admitted to the ward of the Department of Rheumatology and Immunology, Peking University People's Hospital, from January 2005 to February 2008. All patients fulfilled the revised American College of Rheumatology criteria for RA<sup>20</sup>. Synovial fluids (SF) were obtained from 17 of the 223 patients at the same time.

Serum samples from 71 healthy blood donors, 48 patients with pSS, and 40 patients with OA were used as controls. Serum samples were stored at -80°C until used. No patient was pregnant or menopausal at the time of the study. The study protocol was approved by the ethics committee of Peking University People's Hospital (FWA00001384).

**TNF- $\alpha$  blockade therapy.** We also collected serum from another 40 patients with RA who received infliximab therapy, 3 mg/kg, infused 4 times, at Weeks 0, 2, 8, and 16. Serum samples were collected before and after 4 dosings (Weeks 0 and 16) from January 2008 to June 2009. These patients also received traditional disease-modifying antirheumatic drugs (DMARD), including methotrexate, leflunomide, and hydroxychloroquine. The dosage and frequency of the DMARD remained constant throughout the TNF blockade therapy.

**Assay for serum and synovial fluid IL-33.** Serum and synovial fluid IL-33 concentration was determined with a quantitative sandwich ELISA kit (R&D Systems, Minneapolis, MN, USA). Detection limit was 23 pg/ml. Polystyrene microplates were coated overnight with goat anti-human IL-33 antibody (0.8 g/ml) and then blocked with 1% bovine serum albumin in phosphate buffered saline (PBS) for 2 h at room temperature. Serum samples diluted 1:4 in PBS were incubated 2 h at room temperature. Serum IL-33 was determined with biotinylated goat anti-human IL-33. The reaction was developed with streptavidin-horseradish peroxidase, and optical density was read at 450 nm.

**Clinical data and inflammation marker analysis.** All patients were followed up for complete clinical data: age, sex, disease duration, number of swollen joints, number of tender joints, global visual analog scale score, immunoglobulins (IgG, IgM, IgA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), antikeratin antibodies (AKA), antiperinuclear factor (APF), anticitrullinated peptide antibodies, and rheumatoid factor (RF)-IgM, RF-IgA and RF-IgG.

ESR was evaluated by the Westergren method. Values  $\leq$  15 mm/h for men and  $\leq$  20 mm/h for women were considered normal. CRP and immunoglobulins were examined by immunonephelometry method. Values  $>$  7.9 mg/l for CRP were considered positive. AKA and APF were tested by indirect immunofluorescence assay. Anti-citrullinated peptide (anti-CCP) antibodies, RF-IgA, and RF-IgG were tested by ELISA, with normal ranges of 0–120 U/ml and 0–110 U/ml. The 28-joint count Disease Activity Score (DAS28) was calculated as described<sup>21</sup>.

**Statistical analysis.** Results are presented as the mean  $\pm$  SD and percentage. Data analyses were performed using SPSS for Windows, version 13.0. The Mann-Whitney U test was used to analyze the serum IL-33 differences between each group. Student's t test was applied to compare quantitative data between IL-33 undetectable and detectable groups. Qualitative data were compared by the chi-squared test. Potential correlation between IL-33 and clinical characteristics was examined using Spearman's rank correlation

test (for quantitative data) or the Wilcoxon signed-rank test (for qualitative data). P values  $<$  0.05 were considered significant.

## RESULTS

**Patients.** The mean age of the 223 patients with RA at the time of our study was  $55.9 \pm 13.9$  years (range 15–93) and the mean disease duration was  $61.8 \pm 91.3$  months (range 1–480). Major clinical and laboratory features are presented in Table 1. RF-IgM and anti-CCP antibodies were positive in 158 (70.9%) patients. RF-IgA, RF-IgG, AKA, and APF were detected in 12.6%, 33.6%, 35.4%, and 29.6% of the patients with RA, respectively. The presence of RF in RA serum was similar to that of patients with pSS (70.9% vs 68.8%).

**IL-33 level was elevated in sera and SF of patients with RA.** IL-33 was detectable in 94 of the 223 patients with RA (42.2%; Figure 1A), range 0–10068.16 pg/ml (median 0). IL-33 serum concentration was significantly higher in patients with RA than in age-matched healthy controls ( $392.0 \pm 889.4$  pg/ml, vs  $7.0 \pm 37.6$  pg/ml;  $p <$  0.001), patients with pSS ( $392.0 \pm 889.4$  pg/ml, vs  $34.06 \pm 45.51$  pg/ml;  $p =$  0.006), and patients with OA ( $392.0 \pm 889.4$  pg/ml vs  $7.9 \pm 34.9$  pg/ml;  $p <$  0.001) by the Mann-Whitney U test.

IL-33 was also measured in 17 matched samples of both RA SF and sera. IL-33 in SF was detectable in 47.1% (8/17) of patients with RA. The level of IL-33 in SF was similar to the level in sera in these 17 patients ( $209.1 \pm 495.7$  pg/ml vs  $199.7 \pm 452.4$  pg/ml;  $p =$  0.889; Figure 1B).

The association between the clinical features and IL-33 levels is presented in Table 2. The serum IL-33 level was higher in patients with longer disease duration ( $r =$  0.145,  $p =$  0.03), and higher total IgM ( $r =$  0.16,  $p =$  0.017), RF-Ig

Table 1. Clinical and laboratory features in 223 patients with rheumatoid arthritis. Clinical characteristics are presented as mean  $\pm$  SD.

Characteristics	Values (%)
Age, yrs	55.9 $\pm$ 13.9
Men/women	62/161
Disease duration, mo	61.8 $\pm$ 91.3
Tender joint count, 0–46 joints	7.8 $\pm$ 8.4
Swollen joint count, 0–48 joints	6.1 $\pm$ 7.2
DAS28	5.1 $\pm$ 1.4
ESR, mm/h	60.1 $\pm$ 34.0
CRP, mg/l	38.1 $\pm$ 52.8
RF-IgM-positive	158 (70.9)
RF-IgA-positive	28 (12.6)
RF-IgG-positive	75 (33.6)
AKA-positive	79 (35.4)
APF-positive	66 (29.6)
Anti-CCP-positive	158 (70.9)

DAS28: 28-joint count Disease Activity Score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; AKA: antikeratin antibodies; APF: antiperinuclear factor; Anti-CCP: anticitrullinated peptide antibody.




Figure 1. A. Serum and synovial fluid IL-33 concentration, measured by ELISA, in patients with rheumatoid arthritis (RA) and in controls. Sera were obtained from 223 patients with RA, 48 patients with primary Sjögren's syndrome (pSS), 40 patients with osteoarthritis (OA), and 71 healthy controls. Mann-Whitney U test was used for differences between groups. B. Similar levels of IL-33 were detected in RA synovial fluid (SF) compared with sera ( $p = 0.889$ ). IL-33 was elevated in 47.1% (8/17) of RA SF.

( $r = 0.347$ ,  $p < 0.001$ ), and anti-CCP antibody concentrations ( $r = 0.253$ ,  $p < 0.001$ ; Table 2 and Figure 2). The duration of disease in IL-33-positive patients ranged from 1 to 396 months (median 17 months). Nearly half (45/94) of the patients' disease duration was  $\leq 12$  months, suggesting that IL-33 could become elevated at early stages of RA.

#### Serum IL-33 and disease activity in RA. A sample with

Table 2. Correlation analysis for serum IL-33 and clinical data.

Measurements	Spearman Rank Correlation Coefficient (r)	p
Age	-0.5	0.461
Disease duration	0.145	0.03*
Tender joint count, 0-46 joints	0.013	0.846
Swollen joint count, 0-48 joints	0.053	0.431
ESR	-0.008	0.906
CRP	-0.033	0.619
DAS28	0.027	0.693
IgA	0.078	0.249
IgG	-0.08	0.235
IgM	0.16	0.017**
Rheumatoid factor	0.347	< 0.001**
Anti-CCP	0.253	< 0.001**

\*  $p < 0.01$ . \*\*  $p < 0.05$ . ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS: 28-joint count Disease Activity Score; anti-CCP: anti-citrullinated peptide antibodies.

undetectable IL-33 (detection limit was 23 pg/ml) was arbitrarily defined as 0 pg/ml. The 223 patients were then categorized into IL-33-positive and IL-33-negative groups. The characteristics of these 2 groups are shown in Table 3. The 2 groups did not differ significantly in the following features: age ( $56.3 \pm 14.3$  vs  $55.3 \pm 13.2$  yrs;  $p = 0.58$ ), disease duration ( $59.2 \pm 96.6$  vs  $65.4 \pm 84.0$  mo;  $p = 0.62$ ), and female sex (69.8% vs 75.5%;  $p = 0.34$ ).

The 2 groups had similar tender joint count ( $7.4 \pm 7.8$  vs  $8.3 \pm 9.1$ ;  $p = 0.39$ ), swollen joint count ( $5.7 \pm 6.9$  vs  $6.6 \pm 7.6$ ;  $p = 0.36$ ), and DAS28 score ( $5.0 \pm 1.3$  vs  $5.1 \pm 1.6$ ;  $p = 0.59$ ). Markers for inflammation (e.g., ESR and CRP) were also comparable in the IL-33-positive and the IL-33-negative groups. Similarly, SF IL-33 levels were not correlated with disease duration, inflammation markers, DAS28 score, or radiographic stage (data not shown).

**Serum IL-33 and autoantibody production in RA.** The IL-33-positive group had higher levels of RF than the IL-33-negative group ( $521.6 \pm 764.3$  vs  $223.8 \pm 514.0$  pg/ml;  $p = 0.001$ ). Anti-CCP was also significantly higher in the IL-33-positive group compared with the IL-33-negative group ( $336.5 \pm 358.4$  vs  $159.0 \pm 279.0$  pg/ml;  $p < 0.001$ ).

Similarly, the frequency of several other autoantibodies, including RF-IgG (52.1% vs 20.2%;  $p < 0.001$ ), AKA (46.8% vs 27.1%;  $p = 0.002$ ), and APF (42.6% vs 20.2%;  $p < 0.001$ ) was also higher in the IL-33-positive group com-








Figure 2. Correlation between serum IL-33 and concentrations of IgM, rheumatoid factor (RF), and anticitrullinated peptide antibodies (anti-CCP). Spearman's rank correlation test was used to assess correlations. Association of IL-33 to antikeratin antibodies (AKA) and antiperinuclear factor (APF) was analyzed using Wilcoxon signed-rank test.

**Table 3.** Measurements of inflammation, disease activity, and autoantibodies in patients with and without IL-33 in serum. Numerical data presented as mean  $\pm$  SD and analyzed using the t test; the chi-squared test.

Measure	Serum IL-33		t (chi-squared)	p
	IL-33-, n = 129	IL-33+, n = 94		
Age, yrs	56.3 $\pm$ 14.3	55.3 $\pm$ 13.2	0.55	0.583
Disease duration, mo	59.2 $\pm$ 96.6	65.4 $\pm$ 84.0	-0.498	0.619
Men/women	39/90	23/71	0.9	0.343
Tender joint count	7.4 $\pm$ 7.8	8.3 $\pm$ 9.1	-0.858	0.392
Swollen joint count	5.7 $\pm$ 6.9	6.6 $\pm$ 7.6	-0.911	0.363
DAS28	5.0 $\pm$ 1.3	5.1 $\pm$ 1.6	-0.547	0.585
ESR, mm/h	59.7 $\pm$ 34.0	60.6 $\pm$ 34.2	-0.197	0.844
CRP, mg/l	41.1 $\pm$ 63.3	34.0 $\pm$ 33.0	1.091	0.276
IgM, g/l	1.2 $\pm$ 0.6	1.4 $\pm$ 0.9	-1.921	0.056
IgG, g/l	15.5 $\pm$ 5.0	14.5 $\pm$ 4.5	1.476	0.141
IgA, g/l	3.1 1.3	3.4 $\pm$ 1.6	-1.267	0.206
RF-IgM, U/ml	223.8 $\pm$ 514.0	521.6 $\pm$ 764.3	-3.276	0.001*
RF-IgA-positive	12 (9.3%)	16 (17.0%)	2.951	0.086
RF-IgG-positive	26 (20.2%)	49 (52.1%)	24.9	< 0.001*
AKA-positive	35 (27.1%)	44 (46.8%)	9.203	0.002*
APF-positive	26 (20.2%)	40 (42.6%)	13.1	< 0.001*
Anti-CCP, U/ml	159.0 $\pm$ 279.0	336.5 $\pm$ 358.4	-4.001	< 0.001*

\* p < 0.01. DAS28: 28-joint count disease activity score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; AKA: antikeratin antibodies; APF: antiperinuclear factor; Anti-CCP: anticitrullinated peptide antibody.

pared with the IL-33-negative group. A slightly higher level of RF-IgA in the former group did not reach statistical significance (p = 0.086). Together, RF (IgM and IgG), AKA, APF, and anti-CCP levels were significantly higher in the IL-33-positive group than in the IL-33-negative group, as shown in Table 3.

A correlation analysis showed that in patients with RA, IL-33 concentration was positively correlated with the anti-CCP level (Figure 2), RF-IgM, and IgM. IL-33 concentration in AKA-positive patients was significantly higher than that in AKA-negative patients. A similar trend was identified in APF-positive patients (Figure 2).

**Serum IL-33 level and previous treatment.** DMARD were used in 69.1% (65/94) of the IL-33-positive group and 38.0% (80/129) of the IL-33-negative group of patients. The IL-33-positive group had a higher frequency of DMARD usage than the IL-33-negative group (p = 0.002, Table 4).

**Table 4.** Previous therapies in IL-33-positive and IL-33-negative patients.

Therapy	IL-33- Group, n = 129 (%)	IL-33+ Group, n = 94 (%)
DMARD	49 (38.0)	65 (69.1)
MTX	17 (13.2)	45 (47.9)
LEF	15 (11.6)	25 (26.6)
SSZ	7 (5.4)	16 (17.0)
HQC	21 (16.3)	20 (21.3)
Combination therapy	11 (8.5)	31 (33.0)

DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate; LEF: leflunomide; SSZ: sulfasalazine; HCQ: hydroxychloroquine.

This suggests that the IL-33 serum level was affected by previous DMARD treatment, or that patients in the IL-33-positive group had more severe disease.

**Decreased serum IL-33 with anti-TNF treatment.** During the course of infliximab treatment, another 40 patients experienced partial remission. Prior to the treatment, serum IL-33 levels were below the detection limit in 22 out of the 40 patients. In the remaining 18 patients with detectable serum IL-33 prior to the treatment, IL-33 concentration decreased in 15 patients (83.3%) after the treatment (Figure 3). Overall, serum IL-33 concentration tended to be lower after anti-TNF treatment (587.7  $\pm$  300.8 pg/ml vs 331.5  $\pm$  151.5 pg/ml; p = 0.002).

## DISCUSSION

Our study demonstrated that roughly 40% of patients with RA had detectable levels of IL-33 in serum, supporting the idea that IL-33 is implicated in the pathogenesis of RA. To our surprise, serum IL-33 concentration was not correlated to inflammation markers or disease activity, but to the level of RA-associated autoantibodies, suggesting that IL-33 may be involved in autoantibody production in RA.

IL-33 has been implicated in joint inflammation and destruction in animal models<sup>18,19</sup>. This cytokine was initially described as “nuclear factor from high endothelial venules” due to the presence in the nucleus of high endothelial cells<sup>22</sup>. It remains an interesting issue whether IL-33 is released *in vivo*, especially under disease conditions such as RA. Findings from our study demonstrate that IL-33 can be released into circulation in patients with RA even at an early




Figure 3. Serum IL-33 concentration in patients with rheumatoid arthritis (RA) before and 16 weeks (4 doses) after infliximab treatment. The peripheral blood IL-33 concentration was lower after anti-tumor necrosis factor- $\alpha$  treatment.

stage of the disease, although the molecular size of serum IL-33 has not yet been determined. Matsuyama, *et al* also showed that circulating levels of IL-33 were elevated in 30 of 59 patients with RA and revealed a 30-kDa protein in RA serum by immunoprecipitation, although it could be detected in only 1 patient<sup>23</sup>.

The molecular mechanism for IL-33 release is not fully understood as this IL-1 family member lacks an apparent secretory signal peptide. Because of its homology to IL-1 $\beta$  and IL-18, IL-33 was believed to be synthesized as an inactive 31-kDa precursor in the cell and liberated by caspase-1 in response to inflammatory stimuli<sup>24,25,26</sup>. Lüthi, *et al* recently showed that human and mouse full-length IL-33 possesses potent biological activities regulating transcription through its DNA-binding motif *in vitro*<sup>27</sup>. In response to a variety of DNA-damaging agents and when treated with anti-Fas, TNF-related apoptosis-inducing ligand, or TNF- $\alpha$  plus cycloheximide, IL-33 was processed during apoptosis that involved caspase 3 and 7<sup>27,28</sup>. Importantly, this process led to inactivation of IL-33 rather than its activation<sup>29</sup>. However, processed IL-33 is largely retained inside apoptotic bodies. Extracellular IL-33 is believed to be released

from necrotic cells without caspase processing, rather than from apoptotic cells, which inactivate IL-33<sup>27,29</sup>. Consistent with this notion, it seems that a substantial portion of the circulating serum IL-33 is full-length pro-IL-33, as shown by immunoprecipitation in RA serum<sup>23</sup>.

Synovial fibroblasts are believed to be one of the main sources of IL-33 in RA, producing huge amounts of IL-33 in the presence of TNF- $\alpha$  stimulation *in vitro*<sup>18</sup>. According to this concept, we evaluated the role of anti-TNF treatment on serum IL-33 concentrations before and after infliximab treatment. Results from our study showed a trend of decreasing serum IL-33 concentration after anti-TNF treatment, suggesting that TNF- $\alpha$  is at least partly responsible for the overproduction of IL-33 in patients with RA.

Evidence suggests that IL-33 may function as a cytokine through receptors (e.g., ST2) on effector cells<sup>15,16,30,31</sup>, and stimulate the secretion of proinflammatory and Th2 cell-associated cytokines via the nuclear factor- $\kappa$ B-mediated pathways from mast cells<sup>32,33,34,35</sup> and other immune cells<sup>35,36,37,38</sup>. Although caspase-mediated processing inactivates IL-33 and prevents accidentally released IL-33 from stimulating the ST2, cell death by necrosis could release significant amounts of IL-33 because unprogrammed cell death caused by ischemia or activated complement is a prominent feature of RA<sup>39,40</sup>. *In vivo* data showed that administration of IL-33 exacerbates experimental arthritis<sup>18</sup>. Therefore, it seems reasonable to assume that serum IL-33 is related to disease activity. However, in our study no correlation was found between serum IL-33 concentration and the disease activity or markers for inflammation (e.g., the acute-phase inflammation reactant in RA).

Matasuyama, *et al* reported that serum IL-33 was related to RA disease activity<sup>23</sup>. As we did not find the association between IL-33 level and DAS28 score in our study, this discrepancy may be explained by several factors. First, patients recruited for our study showed higher disease activity than the patients described by Matasuyama, *et al*. Second, the demographic characteristics of the patients may differ in these 2 studies. Third, previous DMARD treatment may be different and may affect serum IL-33 levels. Fourth, more subjects were recruited in our study. However, the CRP level was not significantly different between the IL-33 detectable and undetectable groups in Matasuyama's report, suggesting that the serum IL-33 level may not be related to the intensity of the inflammation.

That serum IL-33 concentration is not related to the disease activity suggests the complex or indirect character of the link between IL-33 and RA. It is still early to conclude that IL-33 is not associated with RA severity. More detailed investigations are required to further understand the precise role of IL-33 in RA pathogenesis in different patients with RA who have different disease categories, durations, and treatments. However, from a practical point of view, our data imply that neutralization of circulating IL-33, for exam-

ple using soluble ST2, may not control the inflammation and disease activity in RA directly.

Interestingly, we found serum IL-33 concentration correlated with the concentrations of RF and anticitrullinated protein/peptide antibodies (including AKA, APF, and anti-CCP), 2 recognized risk factors for poor prognosis in RA<sup>41,42,43,44,45</sup>. Whether IL-33 could be used as a prognosis marker is of great interest. Perhaps more importantly, our findings raised the possibility that IL-33 may contribute to abnormal B cell autoimmunity, although a direct pathogenic role of IL-33 in the generation of autoantibodies could not be substantiated.

Although different cell types may play pathogenic roles in RA, a prominent participation of the B cell has been recently highlighted. B cells have emerged as a new target in RA. IL-33 drives production of Th2-associated cytokines including IL-5 and IL-13, which can promote B cell function such as autoantibody production<sup>15</sup>. Thus IL-33 may be indirectly involved in B cell-mediated pathology in RA.

IL-33 may also contribute to the antibody overproduction by inducing mast cell activation. IL-33 is one of the strongest stimuli for mast cells that reside in the synovial tissue<sup>30</sup>. Both human and animal studies have shown that extracellular IL-33 could stimulate the maturation and activation of mast cells<sup>30,32,35</sup>. Mast cells have been confirmed to be a cellular link between autoantibodies and inflammatory arthritis<sup>46,47</sup>. This might be the mechanism underlying our data that IL-33 level is associated with RA-related autoantibodies. In support of this hypothesis, IL-33 contributes to the antibody response and the severity of inflammation in a serum-induced arthritis mouse model that is mast cell-dependent<sup>48</sup>. Our data presented new evidence on the involvement of the new cytokine IL-33 in abnormal humoral immunity. This may ultimately help in understanding the complex issue of autoimmunity in RA.

The limitation of this study is that the commercial IL-33 ELISA reagents have been generated and tested using an *Escherichia coli*-produced portion of hIL-33 (amino acids 112-270). IL-33 released from necrotic cells is full-length pro-IL-33. Thus, an independent ELISA assay using full-length pro-IL-33 to verify our results would be of great help.

We found that serum IL-33 is significantly and selectively increased in RA. It is not a sensitive marker of disease activity, but rather a part of the complicated autoimmune abnormality that is characteristic of RA.

## REFERENCES

1. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. *J Clin Invest* 2008;118:3537-45.
2. Gravalles EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. *Arthritis Rheum* 2000;43:2143-51.
3. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. *Nat Rev Immunol* 2007;7:429-42.
4. Scheinecker C, Redlich K, Smolen JS. Cytokines as therapeutic targets: advances and limitations. *Immunity* 2008;28:440-4.
5. Keystone EC, Shore A, Miller RG, Tan P, Poplonski L, Leary P, et al. Evidence for activated peripheral blood T-cells in rheumatoid arthritis. *J Rheumatol Suppl* 1983;11:85-92.
6. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. *Proc Natl Acad Sci USA* 2000;97:9203-8.
7. Fekete A, Soos L, Szekanez Z, Szabo Z, Szodoray P, Barath S, et al. Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. *J Autoimmun* 2007;29:154-63.
8. Bugatti S, Codullo V, Caporali R, Montecucco C. B cells in rheumatoid arthritis. *Autoimmun Rev* 2007;7:137-42.
9. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med* 2001;344:907-16.
10. Nandakumar KS, Holmdahl R. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. *Arthritis Res Ther* 2006;8:223.
11. Nawata Y, Eugui EM, Lee SW, Allison AC. IL-6 is the principal factor produced by synovia of patients with rheumatoid arthritis that induces B-lymphocytes to secrete immunoglobulins. *Ann NY Acad Sci* 1989;557:230-8, discussion 9.
12. Lettesjo H, Ridderstad A, Moller E. IgG2b inducing factor from rheumatoid arthritis synovial fluid synergizes with transforming growth factor-beta in promoting IgG2b antibody production in mouse B lymphocytes. *Scand J Immunol* 1997;45:50-4.
13. Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. Targeting TNF alpha for the therapy of rheumatoid arthritis. *Clin Exp Rheumatol* 1994;12 Suppl 11:S63-6.
14. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. *Immunol Rev* 2008;223:7-19.
15. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity* 2005;23:479-90.
16. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. *J Immunol* 2007;179:2551-5.
17. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. *Proc Natl Acad Sci USA* 2007;104:282-7.
18. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. *Proc Natl Acad Sci USA* 2008;105:10913-8.
19. Palmer G, Talbot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. *Arthritis Rheum* 2009;60:738-49.
20. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. *Arthritis Rheum* 1992;35:498-502.
21. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44-8.
22. Baekkevold ES, Roussigne M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. *Am J Pathol* 2003;163:69-79.
23. Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. *J Rheumatol* 2010;37:18-25.

24. Lamkanfi M, Dixit VM. IL-33 raises alarm. *Immunity* 2009;31:5-7.
25. Keller M, Ruegg A, Werner S, Beer HD. Active caspase-1 is a regulator of unconventional protein secretion. *Cell* 2008;132:818-31.
26. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. *Cell* 2006;126:659-62.
27. Lüthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. *Immunity* 2009;31:84-98.
28. Talbot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. *J Biol Chem* 2009;284:19420-6.
29. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. *Proc Natl Acad Sci USA* 2009;106:9021-6.
30. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. *J Immunol* 2007;179:2051-4.
31. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. *J Clin Invest* 2007;117:1538-49.
32. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. *Lab Invest* 2007;87:971-8.
33. Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-Fc epsilon RI signals. *J Leukoc Biol* 2007;82:1481-90.
34. Moulin D, Donze O, Talbot-Ayer D, Mezin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. *Cytokine* 2007;40:216-25.
35. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. *Proc Natl Acad Sci USA* 2007;104:18660-5.
36. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. *J Allergy Clin Immunol* 2008;121:1484-90.
37. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. *Int Immunol* 2008;20:1019-30.
38. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. *Blood* 2009;113:1526-34.
39. Andersson U, Erlandsson-Harris H. HMGB1 is a potent trigger of arthritis. *J Intern Med* 2004;255:344-50.
40. Han MK, Kim JS, Park BH, Kim JR, Hwang BY, Lee HY, et al. NF-kappaB-dependent lymphocyte hyperadhesiveness to synovial fibroblasts by hypoxia and reoxygenation: potential role in rheumatoid arthritis. *J Leukoc Biol* 2003;73:525-9.
41. Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A, et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. *Rheumatology* 2003;42:939-46.
42. Vander Cruyssen B, Hoffman IE, Peene I, Union A, Mielants H, Meheus L, et al. Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. *Ann Rheum Dis* 2007;66:364-9.
43. Mimori T. Clinical significance of anti-CCP antibodies in rheumatoid arthritis. *Intern Med* 2005;44:1122-6.
44. Hoffman IE, Peene I, Pottel H, Union A, Hulstaert F, Meheus L, et al. Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. *Clin Chem* 2005;51:261-3.
45. Ding B, Padyukov L, Lundstrom E, Seielstad M, Plenge RM, Oksenberg JR, et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. *Arthritis Rheum* 2009;60:30-8.
46. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. *Science* 2002;297:1689-92.
47. Nigrovic PA, Binstadt BA, Monach PA, Johnsen A, Gurish M, Iwakura Y, et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. *Proc Natl Acad Sci USA* 2007;104:2325-30.
48. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, et al. IL-33 exacerbates autoantibody-induced arthritis. *J Immunol* 2010;184:2620-6.